BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

311 related articles for article (PubMed ID: 24889687)

  • 1. Upregulation of FGFR1 expression is associated with parathyroid carcinogenesis in HPT-JT syndrome due to an HRPT2 splicing mutation.
    Lee JY; Kim SY; Mo EY; Kim ES; Han JH; Maeng LS; Lee AH; Eun JW; Nam SW; Moon SD
    Int J Oncol; 2014 Aug; 45(2):641-50. PubMed ID: 24889687
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tumor suppressor gene mutation in a patient with a history of hyperparathyroidism-jaw tumor syndrome and healed generalized osteitis fibrosa cystica: a case report and genetic pathophysiology review.
    Parfitt J; Harris M; Wright JM; Kalamchi S
    J Oral Maxillofac Surg; 2015 Jan; 73(1):194.e1-9. PubMed ID: 25511968
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Familial isolated primary hyperparathyroidism/hyperparathyroidism-jaw tumour syndrome caused by germline gross deletion or point mutations of CDC73 gene in Chinese.
    Kong J; Wang O; Nie M; Shi J; Hu Y; Jiang Y; Li M; Xia W; Meng X; Xing X
    Clin Endocrinol (Oxf); 2014 Aug; 81(2):222-30. PubMed ID: 24716902
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Analysis of aberrantly spliced HRPT2 transcripts and the resulting proteins in HPT-JT syndrome.
    Moon S; Kim JH; Shim JY; Ahn YB; Song KH; Cha BY; Maeng LS; Han JH
    Mol Genet Metab; 2010 Aug; 100(4):365-71. PubMed ID: 20541447
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genetic analyses in patients with familial isolated hyperparathyroidism and hyperparathyroidism-jaw tumour syndrome.
    Mizusawa N; Uchino S; Iwata T; Tsuyuguchi M; Suzuki Y; Mizukoshi T; Yamashita Y; Sakurai A; Suzuki S; Beniko M; Tahara H; Fujisawa M; Kamata N; Fujisawa K; Yashiro T; Nagao D; Golam HM; Sano T; Noguchi S; Yoshimoto K
    Clin Endocrinol (Oxf); 2006 Jul; 65(1):9-16. PubMed ID: 16817812
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Somatic and germ-line mutations of the HRPT2 gene in sporadic parathyroid carcinoma.
    Shattuck TM; Välimäki S; Obara T; Gaz RD; Clark OH; Shoback D; Wierman ME; Tojo K; Robbins CM; Carpten JD; Farnebo LO; Larsson C; Arnold A
    N Engl J Med; 2003 Oct; 349(18):1722-9. PubMed ID: 14585940
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Loss of nuclear expression of parafibromin distinguishes parathyroid carcinomas and hyperparathyroidism-jaw tumor (HPT-JT) syndrome-related adenomas from sporadic parathyroid adenomas and hyperplasias.
    Gill AJ; Clarkson A; Gimm O; Keil J; Dralle H; Howell VM; Marsh DJ
    Am J Surg Pathol; 2006 Sep; 30(9):1140-9. PubMed ID: 16931959
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characterization of a novel CDC73 gene mutation in a hyperparathyrodism-jaw tumor patient affected by parathyroid carcinoma in the absence of somatic loss of heterozygosity.
    Ciuffi S; Cianferotti L; Nesi G; Luzi E; Marini F; Giusti F; Zonefrati R; Gronchi G; Perigli G; Brandi ML
    Endocr J; 2019 Apr; 66(4):319-327. PubMed ID: 30799315
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Detection of the first gross CDC73 germline deletion in an HPT-JT syndrome family.
    Cascón A; Huarte-Mendicoa CV; Javier Leandro-García L; Letón R; Suela J; Santana A; Costa MB; Comino-Méndez I; Landa I; Sánchez L; Rodríguez-Antona C; Cigudosa JC; Robledo M
    Genes Chromosomes Cancer; 2011 Nov; 50(11):922-9. PubMed ID: 21837707
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Frequent large germline HRPT2 deletions in a French National cohort of patients with primary hyperparathyroidism.
    Bricaire L; Odou MF; Cardot-Bauters C; Delemer B; North MO; Salenave S; Vezzosi D; Kuhn JM; Murat A; Caron P; Sadoul JL; Silve C; Chanson P; Barlier A; Clauser E; Porchet N; Groussin L;
    J Clin Endocrinol Metab; 2013 Feb; 98(2):E403-8. PubMed ID: 23293331
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genetic analyses of the HRPT2 gene in primary hyperparathyroidism: germline and somatic mutations in familial and sporadic parathyroid tumors.
    Cetani F; Pardi E; Borsari S; Viacava P; Dipollina G; Cianferotti L; Ambrogini E; Gazzerro E; Colussi G; Berti P; Miccoli P; Pinchera A; Marcocci C
    J Clin Endocrinol Metab; 2004 Nov; 89(11):5583-91. PubMed ID: 15531515
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Novel IVS2-1G>A mutation causes aberrant splicing of the HRPT2 gene in a family with hyperparathyroidism-jaw tumor syndrome.
    Moon SD; Park JH; Kim EM; Kim JH; Han JH; Yoo SJ; Yoon KH; Kang MI; Lee KW; Son HY; Kang SK; Oh SJ; Kim KM; Yoon SJ; Park JG; Kim IJ; Kang HC; Hong SW; Kim KR; Cha BY
    J Clin Endocrinol Metab; 2005 Feb; 90(2):878-83. PubMed ID: 15613436
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Early-onset, severe, and recurrent primary hyperparathyroidism associated with a novel CDC73 mutation.
    Shibata Y; Yamazaki M; Takei M; Uchino S; Sakurai A; Komatsu M
    Endocr J; 2015; 62(7):627-32. PubMed ID: 25959515
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Large intragenic deletion of CDC73 (exons 4-10) in a three-generation hyperparathyroidism-jaw tumor (HPT-JT) syndrome family.
    Guarnieri V; Seaberg RM; Kelly C; Jean Davidson M; Raphael S; Shuen AY; Baorda F; Palumbo O; Scillitani A; Hendy GN; Cole DEC
    BMC Med Genet; 2017 Aug; 18(1):83. PubMed ID: 28774260
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Novel Mutation in a Patient with Hyperparathyroidism-Jaw Tumour Syndrome.
    Bellido V; Larrañaga I; Guimón M; Martinez-Conde R; Eguia A; Perez de Nanclares G; Castaño L; Gaztambide S
    Endocr Pathol; 2016 Jun; 27(2):142-6. PubMed ID: 26995009
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mice deleted for cell division cycle 73 gene develop parathyroid and uterine tumours: model for the hyperparathyroidism-jaw tumour syndrome.
    Walls GV; Stevenson M; Lines KE; Newey PJ; Reed AAC; Bowl MR; Jeyabalan J; Harding B; Bradley KJ; Manek S; Chen J; Wang P; Williams BO; Teh BT; Thakker RV
    Oncogene; 2017 Jul; 36(28):4025-4036. PubMed ID: 28288139
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Loss of parafibromin expression in a subset of parathyroid adenomas.
    Juhlin C; Larsson C; Yakoleva T; Leibiger I; Leibiger B; Alimov A; Weber G; Höög A; Villablanca A
    Endocr Relat Cancer; 2006 Jun; 13(2):509-23. PubMed ID: 16728578
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Parafibromin mutations in hereditary hyperparathyroidism syndromes and parathyroid tumours.
    Bradley KJ; Cavaco BM; Bowl MR; Harding B; Cranston T; Fratter C; Besser GM; Conceição Pereira M; Davie MW; Dudley N; Leite V; Sadler GP; Seller A; Thakker RV
    Clin Endocrinol (Oxf); 2006 Mar; 64(3):299-306. PubMed ID: 16487440
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HRPT2, a tumor suppressor gene for hyperparathyroidism-jaw tumor syndrome.
    Wang PF; Tan MH; Zhang C; Morreau H; Teh BT
    Horm Metab Res; 2005 Jun; 37(6):380-3. PubMed ID: 16001331
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HRPT2 mutations are associated with malignancy in sporadic parathyroid tumours.
    Howell VM; Haven CJ; Kahnoski K; Khoo SK; Petillo D; Chen J; Fleuren GJ; Robinson BG; Delbridge LW; Philips J; Nelson AE; Krause U; Hammje K; Dralle H; Hoang-Vu C; Gimm O; Marsh DJ; Morreau H; Teh BT
    J Med Genet; 2003 Sep; 40(9):657-63. PubMed ID: 12960210
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.